Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C R Franks

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Cancer|June 15, 1990
Hypothyroidism and goiter in a patient during treatment with interleukin-2V J Mattijssen, P H De Mulder, P A Van Liessum, et al.
European Cytokine Network|October 1, 1990
TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2M Favrot, V Combaret, J Y Blay, et al.
Cancer Research|April 15, 1990
Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factorJ Y Blay, M C Favrot, S Negrier, et al.
Leukemia Research|January 1, 1990
Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot studyD Macdonald, Y Z Jiang, A A Gordon, et al.
Cancer Treatment Reviews|June 1, 1989
Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II studyG Stoter, E Shiloni, S Gundersen, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1989
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II studyG Stoter, E Shiloni, S Aamdal, et al.
Cancer Treatment Reports|June 1, 1986
Phase II study of the platinum analog TNO-6 in patients with advanced ovarian cancerN Colombo, E Sartori, F Landoni, et al.
Experimental Hematology|September 1, 1992
Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumorsA Bosly, T Guillaume, P Brice, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanomaW Fiedler, C Jasmin, P H De Mulder, et al.
Cancer Treatment Reviews|June 1, 1989
A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinomaT J Hamblin, V Inzani, S Sadullah, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Cancer|June 15, 1990
Hypothyroidism and goiter in a patient during treatment with interleukin-2V J Mattijssen, P H De Mulder, P A Van Liessum, et al.
European Cytokine Network|October 1, 1990
TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2M Favrot, V Combaret, J Y Blay, et al.
Cancer Research|April 15, 1990
Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factorJ Y Blay, M C Favrot, S Negrier, et al.
Leukemia Research|January 1, 1990
Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot studyD Macdonald, Y Z Jiang, A A Gordon, et al.
Cancer Treatment Reviews|June 1, 1989
Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II studyG Stoter, E Shiloni, S Gundersen, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1989
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II studyG Stoter, E Shiloni, S Aamdal, et al.
Cancer Treatment Reports|June 1, 1986
Phase II study of the platinum analog TNO-6 in patients with advanced ovarian cancerN Colombo, E Sartori, F Landoni, et al.
Experimental Hematology|September 1, 1992
Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumorsA Bosly, T Guillaume, P Brice, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanomaW Fiedler, C Jasmin, P H De Mulder, et al.
Cancer Treatment Reviews|June 1, 1989
A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinomaT J Hamblin, V Inzani, S Sadullah, et al.
Pageof 10